Arctic Bioscience — Regulatory Filings 2024

Sep 25, 2024

Arctic Bioscience - New cellular research showing anti-psoriatic effects

Arctic Bioscience - New cellular research showing anti-psoriatic effects

Arctic Bioscience are today presenting new research on cells at the EADV

congress in Amsterdam. These cellular data show anti-psoriatic effects from

phospholipid esters from herring roe oil in immune cells and skin cells. These

data contribute to the understanding of how the investigational medicinal

product HRO350 could impact psoriasis, and are supportive data to the ongoing

clinical development program, where the ongoing phase 2b HeROPA clinical trial

in mild-to-moderate psoriasis has a planned read-out later in September/early

October 2024.

"We are very pleased to present additional positive cellular data on the anti

-psoriatic properties related to our investigational medicine, HRO350. Through

these cellular studies, we are increasing our understanding of how HRO350

works", says CEO Christer L. Valderhaug.

The data from the cellular studies show that Phospholipid Esters from Herring

Roe can have immunomodulatory anti-psoriatic effects by affecting signaling on

the IL-17/23 axis in immune cells and psoriatic skin cell models. This increases

the understanding of the potential mode-of-action of HRO350, and are

supplementary to cellular data on effects on Specialized Pro-Resolving Mediators

(SPMs) in immune cells which were presented in June this year (Ringheim-Bakka

2024) as well as previously published data on inflammatory markers in psoriasis

from a clinical study (Petrovic 2023).

"These are exciting data, which show that HRO350 can impact cellular signaling

pathways relevant for psoriasis in both primary human immune cells and psoriasis

skin cell models. We are proud to have conducted this research in Norway, in

collaboration with Nofima and Møreforsking, and we are grateful for the support

from the Research Council of Norway", says Medical Director Runhild Gammelsæter.

The study was conducted in collaboration with Møreforsking and Nofima, and was

supported with a grant from The Research Council of Norway (project nr. 327953,

Properties of phospholipids from Herring Roe in Psoriasis).

Reference: Mildenberger J, Solberg N, Østbye TK, Høst V, Petruccelli F,

Gammelsæter R, Rønning SB, Pedersen ME. "Phospholipid Esters from Herring Roe

promotes SPM biosynthesis in human monocyte-derived macrophages with

implications for the treatment of psoriasis". Poster 3243 at the EADV congress,

Amsterdam, September 25-28th, 2024.

The poster will be made available on the IR tab on the company's webpage.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

Email: christer@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing

pharmaceutical and nutraceutical products based on unique bioactive marine

compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being

developed for treatment of patients with mild-to-moderate psoriasis. This is a

large patient group in need of new effective medicines with beneficial safety

profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as

well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and

highly relevant background.